The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)
Open accessAbstract
Background and aims COVID-19 is a dominant pulmonary disease, with multisystem involvement, depending upon comorbidities. Its profile in patients with pre-existing chronic liver disease (CLD) is largely unknown. We studied the liver injury patterns of SARS-Cov-2 in CLD patients, with or without cirrhosis. Methods Data was collected from 13 Asian countries on patients with CLD, known or newly diagnosed, with confirmed COVID-19. Results Altogether , 228 patients [185 CLD without cirrhosis and 43 with cirrhosis] were enrolled, with comorbidities in nearly 80%. Metabolism associated fatty liver disease (113, 61%) and viral etiology (26, 60%) were common. In CLD without cirrhosis, diabetes [57.7% vs 39.7%, OR = 2.1 (1.1–3.7), p = 0.01] and in cirrhotics, obesity, [64.3% vs. 17.2%, OR = 8.1 (1.9–38.8), p = 0.002] predisposed more to liver injury than those without these . Forty three percent of CLD without cirrhosis presented as acute liver injury and 20% cirrhotics presented with either acute-on-chronic liver failure [5 (11.6%)] or acute decompensation [4 (9%)]. Liver related complications increased (p < 0.05) with stage of liver disease; a Child-Turcotte Pugh score of 9 or more at presentation predicted high mortality [AUROC 0.94, HR = 19.2 (95 CI 2.3–163.3), p < 0.001, sensitivity 85.7% and specificity 94.4%). In decompensated cirrhotics, the liver injury was progressive in 57% patients, with 43% mortality. Rising bilirubin and AST/ALT ratio predicted mortality among cirrhosis patients. Conclusions SARS-Cov-2 infection causes significant liver injury in CLD patients, decompensating one fifth of cirrhosis, and worsening the clinical status of the already decompensated. The CLD patients with diabetes and obesity are more vulnerable and should be closely monitored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationHigh expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa
Xu, H., Zhong, L., Deng, J., Peng, J., Dan, H., Zeng, X., Li, T., & Chen, Q. (2020) · International Journal of Oral Science · doi:10.1038/s41368-020-0074-x · Cited by 2,838
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Liver injury in COVID-19: management and challenges
Zhang, C., Shi, L., & Wang, F.-S. (2020) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(20)30057-1 · Cited by 1,906
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Self-citationCirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
Albillos, A., Lario, M., & Álvarez-Mon, M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.010 · Cited by 1,242 · cited 3×
“Importantly, the SARS-CoV-2 infection produces lymphocytopenia with or without leukopenia, thrombocytopenia and raised fibrinogen degradation products [5, 8, 17], which pre-exist in CLD patients due to bone marrow suppression and cirrhosis associated immune dysfunction syndrome (CAIDS) [18].”
BackgroundThe diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients
Yang, A.-P., Liu, J.-P., Tao, W.-Q., & Li, H.-M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106504 · Cited by 1,138
Cited by
Marjot, T., Moon, A. M., Cook, J. A., Abd-Elsalam, S., Aloman, C., Armstrong, M. J., Pose, E., Brenner, E. J., Cargill, T., Catana, M.-A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.09.024 · Cited by 518
Self-citationCOVID-19 and liver disease: mechanistic and clinical perspectives
Marjot, T., Webb, G. J., Barritt, A. S., Moon, A. M., Stamataki, Z., Wong, V. W., & Barnes, E. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00426-4 · Cited by 385
The overall impact of COVID ‐19 on healthcare during the pandemic: A multidisciplinary point of view
Sabetkish, N., & Rahmani, A. (2021) · Health Science Reports · doi:10.1002/hsr2.386 · Cited by 68
Metadata
- Authors
- Sarin, S. K., Choudhury, A., Lau, G. K., Zheng, M.-H., Ji, D., Abd-Elsalam, S., Hwang, J., Qi, X., Cua, I. H., Suh, J. I., Park, J. G., Putcharoen, O., Kaewdech, A., Piratvisuth, T., Treeprasertsuk, S., Park, S., Wejnaruemarn, S., Payawal, D. A., Baatarkhuu, O., Ahn, S. H., Yeo, C. D., Alonzo, U. R., Chinbayar, T., Loho, I. M., Yokosuka, O., Jafri, W., Tan, S., Soo, L. I., Tanwandee, T., Gani, R., Anand, L., Esmail, E. S., Khalaf, M., Alam, S., Lin, C.-Y., Chuang, W.-L., Soin, A. S., Garg, H. K., Kalista, K., Batsukh, B., Purnomo, H. D., Dara, V. P., Rathi, P., Al Mahtab, M., Shukla, A., Sharma, M. K., Omata, M., & APASL COVID Task Force, A. C. L. I. S. S. (. S.-N. 0.
- Venue
- Hepatology International
- Published
- 2020-07-04
- Volume
- 14
- Issue
- 5
- Pages
- 690-700
- ISSN
- 1936-0533 (ISSN-L)
- 1936-0541
- OpenAlex
- W3038175434
- Cited by
- 296
- References
- 34
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). https://app.cochat.ai/papers/10.1007/s12072-020-10072-8
- The paper
- Sarin, S. K., Choudhury, A., Lau, G. K., Zheng, M.-H., Ji, D., Abd-Elsalam, S., Hwang, J., Qi, X., Cua, I. H., Suh, J. I., Park, J. G., Putcharoen, O., Kaewdech, A., Piratvisuth, T., Treeprasertsuk, S., Park, S., Wejnaruemarn, S., Payawal, D. A., Baatarkhuu, O., . . . APASL COVID Task Force, A. C. L. I. S. S. (. S.-N. 0. (2020). Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study). Hepatology International. https://doi.org/10.1007/s12072-020-10072-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.